Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol Fumarate in COPD
NCT00215449Phase 3Completed
- Sponsor
- Dey
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Formoterol Fumarate with Placebo (2 arms). Primary endpoint: Lung function at 12 weeks. Status: completed.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00215449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215449.